Yahoo
As the U.S. stock market navigates a volatile landscape marked by benign inflation data and fluctuating interest rate expectations, investors are keenly observing opportunities across various sectors. Penny stocks, though often associated with speculative ventures, can offer unique value when supported by strong financials and growth potential. This article will explore three penny stocks that stand out for their robust financial health, presenting intriguing possibilities for investors...
Yahoo
By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Encouraging Interim Results from Phase 2b/3 COMBAT-ALS Trial On December 5, 2024, MediciNova, Inc. (NASDAQ:MNOV) announced a poster presentation at the 35 th International Symposium on ALS/MND would feature a study update and interim analysis results from the ongoing Phase 2b/3 COMBAT-ALS trial of MN-166
Yahoo
LA JOLLA, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces the study update and interim analysis results from the Company’s COMBAT-ALS Phase 2b/3 clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) will be presented at the 35th International Symposium on ALS/MND held December 6-8, 2024 in Montreal,
Yahoo
By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Monetary Damages Due from Sanofi/Novartis Litigation Settlement On November 11, 2024, MediciNova, Inc. (NASDAQ:MNOV) announced a settlement in the patent litigation brought by Genzyme Corporation, a subsidiary of Sanofi, against Novartis. The litigation included a claim for infringement of U.S. Patent No.
Yahoo
NIH-funded Phase 2-3 ALS Expanded Access study expands reach of MediciNova’s ongoing COMBAT-ALS trial and provides illustration of Company’s development strategyLA JOLLA, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) focused on development of novel anti-inflammatory treatments for neurodegenerative diseases, malignant brain cancers, an
Yahoo
LA JOLLA, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a pending patent application for MN-001 (Tipelukast) to cover "Method to Decrease Triglyceride Synthesis in a Liver of a Subject." The allowed claims cover a groundbreaking
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PAYX | -<0.01% | $52.87B | +21.99% | 2.58% |
MAA | <0.01% | $17.61B | +14.58% | 3.93% |
LEVI | -<0.01% | $6.97B | +13.28% | 2.83% |
HCAT | -<0.01% | $334.66M | -44.05% | 0.00% |
RDNT | -0.01% | $4.51B | +63.17% | 0.00% |
MKTX | 0.01% | $8.36B | -16.25% | 1.35% |
LC | -0.01% | $1.84B | +111.53% | 0.00% |
AON | 0.01% | $79.61B | +19.80% | 0.72% |
DOLE | -0.02% | $1.23B | +11.62% | 2.45% |
RXST | -0.03% | $1.26B | -32.74% | 0.00% |
CPS | -0.03% | $263.88M | -8.09% | 0.00% |
TER | 0.03% | $22.40B | +29.76% | 0.35% |
BRC | 0.03% | $3.51B | +23.71% | 1.28% |
MTLS | -0.03% | $464.27M | +31.88% | 0.00% |
MAX | -0.03% | $621.42M | +3.01% | 0.00% |
CFLT | 0.03% | $8.77B | +24.31% | 0.00% |
POWL | -0.04% | $3.10B | +214.96% | 0.41% |
SON | -0.04% | $4.68B | -16.39% | 4.34% |
SNDL | 0.04% | $477.90M | +31.39% | 0.00% |
CLF | -0.04% | $5.15B | -41.53% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
JRVR | -33.95% | $180.45M | -43.15% | 3.32% |
SNDX | -27.65% | $1.11B | -39.00% | 0.00% |
THS | -24.46% | $1.79B | -14.67% | 0.00% |
VOD | -24.43% | $21.57B | +0.35% | 8.67% |
ANGI | -21.21% | $919.95M | -15.53% | 0.00% |
MUR | -20.99% | $4.82B | -13.30% | 3.64% |
BRY | -20.40% | $383.93M | -21.65% | 8.82% |
ETON | -20.11% | $380.34M | +250.00% | 0.00% |
PGY | -19.94% | $653.33M | -32.19% | 0.00% |
NGNE | -19.72% | $369.87M | -41.60% | 0.00% |
AMGN | -19.35% | $144.83B | -11.51% | 3.28% |
TRIN | -19.34% | $865.92M | +3.45% | 13.91% |
WEST | -19.25% | $589.62M | -38.39% | 0.00% |
MOS | -19.19% | $8.49B | -16.81% | 3.13% |
UPST | -18.44% | $5.88B | +107.13% | 0.00% |
GRAL | -18.42% | $584.82M | +2.38% | 0.00% |
IAC | -18.20% | $3.70B | -14.52% | 0.00% |
MNR | -18.01% | $1.82B | +2.15% | 18.25% |
SU | -17.77% | $49.12B | +24.27% | 4.14% |
CIVI | -17.64% | $5.28B | -11.08% | 3.66% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
BTCT | 54.52% | $23.92M | +5.78% | 0.00% |
ALIT | 28.16% | $3.62B | -18.19% | 0.00% |
ALT | 25.59% | $477.25M | -37.81% | 0.00% |
TGI | 21.32% | $1.46B | +23.77% | 0.00% |
NPWR | 20.13% | $687.77M | +6.16% | 0.00% |
LLYVA | 20.12% | $6.25B | +90.73% | 0.00% |
OCX | 19.97% | $35.35M | -36.56% | 0.00% |
LLYVK | 19.09% | $6.41B | +93.35% | 0.00% |
NXTC | 19.03% | $21.45M | -33.39% | 0.00% |
AMTX | 18.82% | $135.78M | -11.65% | 0.00% |
CRON | 18.48% | $753.12M | +0.51% | 0.00% |
GENI | 18.33% | $1.85B | +47.97% | 0.00% |
XBIO | 17.88% | $6.56M | +24.36% | 0.00% |
SHOP | 17.70% | $133.73B | +33.51% | 0.00% |
JWN | 17.51% | $3.98B | +36.40% | 3.15% |
AXSM | 17.33% | $4.54B | +10.88% | 0.00% |
SDGR | 16.94% | $1.36B | -28.06% | 0.00% |
ADBE | 16.08% | $185.84B | -28.09% | 0.00% |
TPB | 15.38% | $1.00B | +127.84% | 0.49% |
TECX | 15.31% | $619.91M | +161.32% | 0.00% |
Current Value
$1.961 Year Return
Current Value
$1.961 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FLTR | 16.24% | $1.98B | 0.14% |
TBIL | 14.93% | $4.83B | 0.15% |
IBTF | 14.64% | $2.24B | 0.07% |
MSOS | 14.00% | $445.91M | 0.83% |
DUSB | 13.95% | $939.32M | 0.15% |
IVOL | 13.59% | $457.45M | 1.02% |
SMMU | 11.68% | $657.96M | 0.35% |
AGZD | 10.08% | $148.43M | 0.23% |
IBDR | 9.79% | $3.12B | 0.1% |
YOLO | 9.49% | $29.81M | 1.03% |
CNBS | 9.49% | $11.68M | 0.77% |
SHYD | 8.50% | $311.16M | 0.35% |
MJ | 8.22% | $146.13M | 0.78% |
VUSB | 8.13% | $4.47B | 0.1% |
FTSD | 8.11% | $226.02M | 0.25% |
URNM | 8.03% | $1.49B | 0.75% |
GSY | 7.49% | $2.45B | 0.23% |
URA | 7.33% | $3.36B | 0.69% |
BSCP | 7.13% | $3.97B | 0.1% |
IGV | 7.11% | $9.64B | 0.41% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
AGZ | 0.02% | $701.03M | 0.2% |
SECT | -0.02% | $1.99B | 0.77% |
VTI | 0.03% | $465.26B | 0.03% |
NUBD | -0.04% | $404.31M | 0.16% |
EWJV | 0.06% | $247.25M | 0.15% |
BETZ | -0.06% | $71.78M | 0.75% |
FTHI | 0.08% | $1.10B | 0.75% |
BKAG | 0.09% | $1.88B | 0% |
FMHI | 0.09% | $751.73M | 0.7% |
RPG | -0.10% | $1.55B | 0.35% |
BUZZ | -0.10% | $67.23M | 0.75% |
SPHQ | 0.10% | $11.77B | 0.15% |
ITOT | -0.12% | $65.03B | 0.03% |
GSLC | 0.13% | $13.33B | 0.09% |
SUSA | 0.14% | $3.80B | 0.25% |
USMC | -0.15% | $2.60B | 0.12% |
TDTT | -0.15% | $1.97B | 0.18% |
IEF | -0.15% | $31.44B | 0.15% |
GSUS | -0.15% | $2.42B | 0.07% |
UCON | 0.17% | $3.37B | 0.85% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IFV | -17.04% | $148.62M | 1.03% |
EWI | -15.29% | $371.72M | 0.5% |
IGBH | -15.17% | $97.62M | 0.14% |
PXE | -15.00% | $108.61M | 0.63% |
HEDJ | -14.64% | $1.52B | 0.58% |
EWW | -13.89% | $1.13B | 0.5% |
GNR | -13.87% | $2.70B | 0.4% |
IEO | -13.73% | $621.50M | 0.4% |
DRLL | -13.71% | $323.08M | 0.41% |
IXC | -13.65% | $1.96B | 0.41% |
TESL | -13.58% | $21.98M | 1.2% |
PFFR | -13.47% | $100.90M | 0.45% |
FCG | -13.45% | $449.90M | 0.6% |
FEP | -13.35% | $184.01M | 0.8% |
XOP | -13.34% | $2.34B | 0.35% |
FLMX | -13.24% | $72.71M | 0.19% |
EUFN | -13.23% | $1.82B | 0.48% |
EFAA | -13.18% | $102.96M | 0% |
ICOW | -13.18% | $1.10B | 0.65% |
IDV | -13.08% | $3.83B | 0.49% |